Market Research Logo

CAR-T Therapies Market, 2018-2030

CAR-T Therapies Market, 2018-2030

INTRODUCTION
Amidst the current initiatives to develop more targeted anti-cancer therapies, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a potent and viable therapeutic intervention to eradicate tumor cells, with minimal side effects. It is based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. There are certain key characteristics that render CAR-T cells suitable for use as effective therapeutic tools; these include target specificity, adaptability and the capability to retain immunologic memory.

Close to 70 academic and research institutes across the globe have made significant contributions to this field, mostly by convening the initial research on potential product candidates. These efforts have built the intellectual framework for the establishment of several start-ups. The ongoing innovation has also led to the discovery of several novel molecular targets, strengthening the research pipelines of various companies engaged in this domain. Given the recent approval of two CAR-T therapies, namely Kymriah® (Novartis) and Yescarta® (Gilead Sciences), and a robust development pipeline, the CAR-T therapy market also offers considerable promise to a number of industry stakeholders.

SCOPE OF THE REPORT
The “CAR-T Therapy Market, 2018-2030” report features an extensive study of the current market landscape and the future potential of CAR-T therapies. One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing development programs of both small and big pharmaceutical firms. Amongst other elements, the report features the following:
An analysis depicting prevalent and emerging trends related to CAR-T therapies as observed on the social media platform, Twitter. In addition to the yearly chatter trends, the analysis highlights the most frequently talked about product candidates as well.
A detailed assessment of the current market landscape of CAR-T therapies with respect to type of developer (industry and non-industry), phase of development, target therapeutic indications, key target antigens, source of T-cells (autologous and allogenic), and route of administration (intravenous infusion and regional route).
Comprehensive profiles of marketed and mid to late stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, history of development, current development status, key clinical trial results, details on administered dose, price and manufacturing process of the therapy (wherever available).
An analysis of the CAR constructs of clinical stage therapies based on generation of CAR-T product (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector (lentivirus, retrovirus, mRNA electroporation, sleeping beauty and other vectors) and type of co-stimulatory domain used.
An analysis of the CAR-T clinical trials registered across the world in the period between 2009 and 2018, highlighting the year wise trend and the geographical distribution.
A detailed analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2X2 analysis to assess the relative experience of certain KOLs, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, indicating the geographical locations of eminent scientists / researchers involved in the development of CAR-T therapies.
An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity offered by oncological and non-oncological disease indications.
A detailed discussion on innovative technology platforms that are being used for the development of CAR-T therapies, along with profiles of key technology providers.
A case study on manufacturing cell therapy products, highlighting the key challenges, and a list of contract service providers and in-house manufacturers that are involved in this space.
An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies, featuring different models / approaches that a pharmaceutical company may choose to adopt to decide the price of its proprietary products that are likely to be marketed in the coming years.
A review of the key promotional strategies that have been adopted by the developers of the marketed CAR-T therapies, Kymriah® and Yescarta®.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. The report includes information on (potential) sales-based revenues of CAR-T therapies that are currently marketed or are in late stages of development. Additionally, it presents detailed segmentation of the overall opportunity on the basis of geography (North America, Europe and Asia Pacific) and target indications (acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, hepatocellular carcinoma and non-Hodgkin’s lymphoma). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individuals:
Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)
Miguel Forte (Chief Operating Officer, TxCell)
Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital).

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. Over 365 CAR-T therapies are presently being developed across various preclinical / clinical stages. Amongst these, two products, namely Kymriah® (Novartis) and Yescarta® (Gilead Sciences), were approved in 2017 for the treatment of acute lymphoblastic leukemia and large B-cell lymphoma, respectively.

2. More than 60% of the pipeline therapies are under clinical evaluation. Of the total number of clinical candidates, close to 100 CAR-T therapies are in the mid to late-stages of development (phase I/II and above) and are anticipated to enter the market in the next 5-10 years. Examples include bb2121 (bluebird bio / Celgene), MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center), EPCAM CAR-T and CD19 CAR-T (Sinobioway Cell Therapy) and mixed CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University).

3. More than 85% of the products in the development pipeline are being developed to treat various types of cancers, which include both hematological malignancies and solid tumors, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia (57), non-Hodgkin's lymphoma (50), multiple myeloma (29), chronic lymphocytic leukemia (28), pancreatic cancer (21), glioblastoma (20), hepatocellular carcinoma (18), breast cancer (16), acute myeloid leukemia (16) and lung cancer (15). Several therapy candidates are also being developed for other therapeutic areas, such as autoimmune disorders and infectious diseases.

4. Amongst the various CAR-T therapies, we observed that 36% are designed to target the CD19 receptor. Other molecular targets that are being investigated for therapy development include CD22, BCMA, Meso, CD20, GD2, CD30, HER1, HER2, EGFRvIII, MUC1, CD33, CD123, PSMA, GPC3, PD-L1, CEA, CD38, EPCAM and PSCA.

5. Over 100 companies, consisting of start-ups, small pharma and big pharma firms, are involved in the development of CAR-T therapies. The key players involved in development of CAR-T therapies (based on the number of candidate therapies in their respective pipelines) include Shanghai GeneChem, Juno Therapeutics, Marino Biotechnology, Cellular Biomedicine Group, Novartis, CARsgen Therapeutics, The Beijing Pregene Science and Technology, Shanghai Unicar-Therapy Bio-Medicine Technology and Celgene.

6. Academic institutions continue to drive the innovation in this domain; many universities and research institutes have played a critical role in the discovery, design and development of novel CAR-T therapies. Currently, around 55% of the pipeline therapies are being developed by academic players, either alone or in collaboration with industry players. The most active non-industry players (based upon the number of therapies under clinical development) include the Baylor College of Medicine (17), National Cancer Institute (13), Shenzhen Geno-immune Medical Institute (13), University of Pennsylvania (13), Southwest Hospital (11), Chinese PLA General Hospital (9), Memorial Sloan Kettering Cancer Center (7), Xinqiao Hospital of Chongqing (6), Peking University (6), Fuda Cancer Hospital (6), City of Hope Medical Center (5) and Sun Yat-sen University (5).

7. Several prominent scientists have made significant contributions in advancing clinical development efforts and, therefore, have emerged as key opinion leaders in this field. We observed that, so far, over 175 investigators, across various regions, have been involved in conducting numerous clinical trials focused on novel CAR-T therapies; examples of some of the most active principle investigators in this domain are (on the basis of number of the clinical trials, and the highest phase of development of the studies with which they were / are affiliated) Dr. Noelle Frey (Abramson Cancer Center of the University of Pennsylvania), Dr. Cheng Qian (Southwest Hospital of Third Military Medical University), Dr. Lung-Ji Chang (Shenzhen Geno-Immune Medical Institute), Dr. Yangyi Bao (The First People's Hospital of Hefei), Dr. Lin Yang (Soochow University), Dr. Xiang Sun (The First People's Hospital of Hefei), Dr. Lizhi Niu (Fuda Cancer Hospital) and Dr. Jiangtao Wang (Ningbo Cancer Hospital).

8. Numerous contract manufacturing organizations (CMOs) with advanced capabilities have also emerged, offering services for manufacturing personalized T-cell based therapies. Examples of such CMOs include (in alphabetical order) Amsterdam Biotherapeutics Unit (AmBTU), apceth Biopharma, Atlantic Bio GMP, Brammer Bio, Cell and Gene Therapy Catapult, Cell Therapies, Cellular Therapeutics, EUFETS, MEDINET, MolMed, PCT, KBI Biopharma and WuXi AppTec.

9. The CAR-T therapy market is projected to grow at an annualized rate of over 51% during the time period 2018-2030. The market, in the long term, is likely to be driven by three indications, namely non-Hodgkin’s lymphoma (74%), acute lymphoblastic leukemia (9%) and multiple myeloma (8%). Moreover, in the long term, several product candidates, such as Kymriah®, Yescarta® and JCAR017 are expected to achieve blockbuster status.

10. In terms of geographical distribution, North America is currently considered to be the major hub for development and manufacturing of T-cell therapies; it is likely to continue to dominate the market over the next decade as well. However, there is a general perception that, owing to the fact that more than 60% of the CAR-T trials are currently being conducted in China, this market is likely to grow at a relatively faster rate as compared to those in the developed regions.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the coming 12 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the CAR-T therapy market in the short to mid-term and long term.

Chapter 3 provides a general overview of CAR-T therapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the conception and historical evolution of cancer immunotherapy, general manufacturing procedures used for the production of T-cell immunotherapies, factors supporting the growing popularity of T-cell based therapies and the challenges associated with such therapeutic options.

Chapter 4 focuses on CAR-T therapies and highlights the prevailing trends pertaining to the ongoing research in this field. It features details on the historical development of CAR-T products, such as the structure of CAR-T constructs (including information on all four generations of CAR-Ts), a discussion on the process of CAR-T development, molecular targets that are currently under investigation (for the development of such therapeutic products) and the current challenges (such as toxicity issues) that are associated with this therapy segment.

Chapter 5 provides insights on the popularity of CAR-T therapies on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2017, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter showcases the most frequently mentioned keywords and drug candidates, as observed on social media.

Chapter 6 provides information on around 366 CAR-T cell therapies that are currently in different stages of development (clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules with respect to the type of developer(s), phase of development, target therapeutic areas and disease indications, key target antigens, source of T-cells (autologous and allogenic) and route of administration (intravenous infusion and regional route). Further, the chapter identifies the most active players (in terms of number of pipeline candidates) and features a logo landscape representation, highlighting product developers in North America, Europe and the Asia Pacific region. In addition, it includes an analysis of the CAR constructs that are presently being used in clinical stage CAR-T therapies on the basis of generation of CAR product, type of binding domain, type of vector and type of co-stimulatory domain.

Chapter 7 presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular targets of CAR-T therapies being developed against hematological cancers and solid tumors. Further, the chapter includes an analysis of global CAR-T trials that were registered in the time period between 2009 to 2018, featuring the year wise trend and distribution of CAR-T trials across different geographies. In addition, it includes a comprehensive analysis of close to 290 clinical trials (completed / ongoing) to evaluate CAR-T therapies with respect to the phase of development, patient segment (children, adults and senior citizens), and type of therapy (monotherapy and combination therapy). To offer due credit to the work of eminent researchers in this domain, we have also mapped the presence of key opinion leaders (who are involved in this field of research) across the globe.

Chapter 8 includes detailed profiles of approved / late stage CAR-T therapies. Each profile features a general overview of the therapy and provides information on its history of development, clinical trial timeline, clinical trial results, manufacturing process, estimated cost of treatment and treatment regimen details.

Chapter 9 highlights the most common therapeutic indications targeted by CAR-T therapies, and features brief discussions on the CAR-T therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.

Chapter 10 provides a list of technology platforms that are either available in the market or under development, for designing and / or manufacturing CAR-T therapies. It features brief profiles of some of the key technologies; each profile contains details on the various pipeline molecules that have been / are being developed using the technology, its advantages and the associated partnerships.

Chapter 11 provides insights on the cell therapy manufacturing process, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining such manufacturing sites. It includes a list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house capabilities. For all the players mentioned in this chapter, we have included details on location of manufacturing facilities, products manufactured, scale of operation and compliance to cGMP standards.

Chapter 12 highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their T-cell based immunotherapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement considerations for T-cell immunotherapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapies.

Chapter 13 features an elaborate discussion on the commercial opportunity associated with CAR-T therapies. It provides a comprehensive market forecast analysis for therapies that are either already approved or are in the mid-phases of clinical development (phase I/II, phase II and phase III), taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed segmentation of the opportunity on the basis of geography (North America, Europe and Asia Pacific) and target indications (acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, hepatocellular carcinoma and non-Hodgkin’s lymphoma).

Chapter 14 highlights the key promotional strategies that are being implemented by the developers of the marketed products, Kymriah® and Yescarta®. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 15 includes brief company profiles of the leading players in the CAR-T therapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T therapies, affiliated technology portfolio (if available), recent developments related to CAR-T therapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 16 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 17 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Enkhtsetseg Purev (Assistant Professor Of Medicine, University Of Colorado), Miguel Forte (Chief Operating Officer, TxCell), Vincent Brichard (Vice President, Immuno-Oncology, Celyad) and Xian-Bao Zhan (Professor Of Medicine and Director, Department Of Oncology, Changhai Hospital).

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 19 is an appendix, which contains the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the report:

1. Abramson Cancer Center
2. Acerta Pharma
3. Adaptimmune Therapeutics
4. Adicet Bio
5. Advent Bioservices
6. Adverum Biotechnologies
7. Aeon Therapeutics (Shanghai)
8. Affiliated Hospital to Academy of Military Medical Sciences
9. AgenTus Therapeutics
10. AGF Private Equity
11. Akron Biotech
12. Allergan
13. Amsterdam BioTherapeutics Unit
14. Amgen
15. Anhui Provincial Hospital
16. Antagene
17. Anterogen
18. apceth Biopharma
19. Aquilo Capital Management
20. ARBELE
21. ARCH Venture Partners
22. ARIAD Pharmaceuticals
23. AstraZeneca
24. Asymptote
25. Atlantic Bio GMP
26. Atlas Venture
27. Aurora Biopharma
28. Autolus
29. Avacta
30. AVG Ventures
31. BankInvest Biomedical Venture
32. Batavia Biosciences
33. Bavarian Nordic
34. Baxalta
35. Bayer
36. Baylor College of Medicine
37. Beijing Biohealthcare Biotechnology
38. Beijing Doing Biomedical
39. Beijing Genomics Institute
40. Beijing Immunochina Medical Science and Technology
41. Beijing Sanwater Biological Technology
42. Bellicum Pharmaceuticals
43. BioAtla
44. Bio Elpida
45. Biogen
46. BioLife Solutions
47. bluebird bio
48. Boehringer Ingelheim
49. Brammer Bio
50. Broad Institute
51. Bristol-Myers Squibb
52. California Institute for Regenerative Medicine
53. Cancer Research UK
54. Cancer Prevention Research Institute of Texas
55. Cartherics
56. Caribou Biosciences
57. Carina Biotech
58. CARsgen Therapeutics
59. Casdin Capital
60. Casebia Therapeutics
61. Cell Biotech
62. Celdara Medical
63. Cellectis
64. Cell Design Labs
65. Celgene
66. Cell and Gene Therapy Catapult
67. Cellenkos
68. Cell Medica
69. Cellular Biomedicine Group
70. CELLforCURE
71. Cell Therapies
72. Cellular Therapeutics
73. Celyad
74. Center for Cell and Gene Therapy
75. Changhai Hospital
76. CHDI Foundation
77. Chiesi Farmaceutici
78. Children's Hospital of Philadelphia
79. Children's Mercy Hospital
80. Children's Oncology Group
81. Children's Research Institute
82. Chinese Academy of Sciences
83. Chinese PLA General Hospital
84. Christie NHS Foundation Trust
85. Clough Capital Partners
86. City of Hope National Medical Center
87. Cognate BioServices
88. Cook MyoSite
89. Cormorant Asset Management
90. CRISPR Therapeutics
91. CureVac
92. Cystic Fibrosis Foundation Therapeutics
93. Cytovance Biologics
94. Daiichi Sankyo
95. Dana-Farber Cancer Institute
96. Dartmouth College
97. Dendreon
98. Dongguan People's Hospital
99. Dow AgroSciences
100. Duke Cancer Institute
101. EcoR1 Capital
102. Editas Medicine
103. Eli Lilly
104. Endocyte
105. ERS Genomics
106. Eutilex
107. Eureka Therapeutics
108. F1 Oncology
109. Fate Therapeutics
110. FGP Capital
111. Financière IDAT
112. First Affiliated Hospital of Chengdu Medical College
113. First Affiliated Hospital of Harbin Medical University
114. First Affiliated Hospital of Wenzhou Medical University
115. First Affiliated Hospital of Zhejiang University
116. First People's Hospital of Foshan
117. Five Prime Therapeutics
118. Forbion Capital Partners
119. Fondazione Telethon and Ospedale San Raffaele
120. Foresite Capital
121. Forevertek Biotechnology
122. Formula Pharmaceuticals
123. Fosun Pharmaceutical
124. Franklin Templeton Investments
125. Fred Hutchinson Cancer Research Center
126. Friedreich’s Ataxia Research Alliance
127. Fuda Cancer Hospital
128. Fudan University
129. Fujian Medical University
130. Gene and Cell Therapy Lab
131. GE Healthcare Life Sciences
132. Gilead Sciences
133. GlaxoSmithKline
134. Google Ventures
135. Green Cross Cell
136. Guangzhou Eighth People's Hospital
137. Guangzhou First People's Hospital
138. Guangzhou Xiangxue Pharmaceutical
139. Guangzhou YiYang Biological Technology
140. Guangdong Zhaotai InVivo Biomedicine
141. Guy's and St Thomas' NHS Foundation Trust
142. Harbin Medical University
143. Harvard University
144. Hebei Senlang Biotechnology
145. Henan Cancer Hospital
146. H. Lee Moffitt Cancer Center and Research Institute
147. Howard Hughes Medical Institute
148. Human Stem Cells Institute
149. Hunan Zhaotai Yongren Medical Innovation
150. iCarTAB BioMed
151. iCell Gene Therapeutics
152. Immunocore
153. Immune Therapeutics
154. Immunovative Therapies
155. Imperial College London
156. Innovative Cellular Therapeutics
157. Innovative Genomics Institute
158. Intellia Therapeutics
159. Intrexon
160. Institut Curie
161. Institut Pasteur
162. Boston Children's Hospital
163. Instituto de Salud Carlos III
164. Iovance Biotherapeutics
165. Iowa State University Research Foundation
166. Janus Capital Management
167. Janssen Biotech
168. Jazz Pharmaceuticals
169. JCR Pharmaceuticals
170. Jennison Associates
171. Jiangsu Cancer Hospital
172. John Goldman Centre for Cellular Therapy
173. Johns Hopkins University
174. Jonsson Comprehensive Cancer Center
175. Juno Therapeutics
176. JW Biotechnology
177. Karolinska University Hospital
178. KBI Biopharma
179. Khosla Ventures
180. King's College London
181. Kite Pharma
182. KTB Ventures
183. Leucid Bio
184. Lexicon Pharmaceuticals
185. Lonza
186. Marino Biotechnology
187. MaSTherCell
188. Massachusetts General Hospital Cancer Center
189. MaxCyte
190. Max Delbrück Center for Molecular Medicine in the Helmholtz Association
191. MD Anderson Cancer Center
192. Medarex
193. Medical College of Wisconsin
194. Medigene
195. MEDINET
196. MedImmune
197. Memorial Sloan Kettering Cancer Center
198. Merck
199. Merck Serono
200. Merlin Nexus
201. Millennium Pharmaceuticals
202. Miltenyi Biotec
203. MingJu Therapeutics (Shanghai)
204. Molecular and Cellular Therapeutics
205. MolMed
206. Mustang Bio
207. Nanjing Children's Hospital
208. Nanjing Legend Biotech
209. NantKwest
210. National Cancer Institute
211. National Heart, Lung, and Blood Institute
212. National Institutes of Health
213. Navy General Hospital (Beijing)
214. New Enterprise Associates
215. New Leaf Venture Partners
216. New River Management
217. NewVa Capital Partners
218. Ningbo Cancer Hospital
219. Nikon CeLL innovation
220. Noile-Immune Biotech
221. Novartis
222. ODYSSEE Venture
223. Omega Funds
224. OnCyte
225. Onyx Pharmaceuticals
226. Opexa Therapeutics
227. Opus Bio
228. OrbiMed HealthCare Fund Management
229. Ospedale Pediatrico Bambino Gesù
230. Oxford BioMedica
231. Partners Innovation Fund
232. Peking University
233. Peter MacCallum Cancer Centre
234. PersonGen BioTherapeutics (Suzhou)
235. Pfizer
236. PharmaCell
237. Pharmicell
238. Pinze Lifetechnology
239. Polaris Partners
240. Poseida Therapeutics
241. Praxis Pharmaceutical
242. Precision BioSciences
243. Precision Genome Engineering
244. Princess Margaret Cancer Centre
245. Progenitor Cell Therapy
246. ProMab Biotechnologies
247. Puma Biotechnology
248. Quogue Capital
249. Ramius Capital Group
250. Rayne Cell Therapy Suite
251. Redmile Group
252. Relieve Genetics
253. Regeneron Pharmaceuticals
254. Remeditex Ventures
255. Renji Hospital
256. Renmin Hospital of Wuhan University
257. Ridgeback Capital Management
258. Roche
259. Rockland Immunochemicals
260. Roger Williams Medical Center
261. RoslinCT
262. Roswell Park Comprehensive Cancer Center
263. Sangamo Therapeutics
264. San Raffaele Hospital
265. Scottish National Blood Transfusion Service
266. Seattle Genetics
267. Seattle Children's Hospital
268. Second Affiliated Hospital of Guangzhou Medical University
269. Sectoral Asset Management
270. Second Military Medical University
271. Servier
272. Shanghai Bioray Laboratory
273. Shanghai Changzheng Hospital
274. Shanghai Chest Hospital
275. Shanghai Children's Medical Center
276. Shanghai GeneChem
277. Shanghai Longyao Biotechnology
278. Shanghai Sunway Biotech
279. Shanghai Tongji Hospital
280. Shanghai Unicar-Therapy Bio-medicine Technology
281. Sheba Medical Center
282. Shenzhen Geno-immune Medical Institute
283. Shenzhen Institute for Innovation and Translational Medicine
284. Shenzhen Second People's Hospital
285. Shenzhen Sibiono GeneTech
286. Shire International
287. Sidney Kimmel Comprehensive Cancer Center
288. Sigma-Aldrich
289. Sichuan University
290. Sinobioway Cell Therapy
291. Sinobioway Group
292. Spark Therapeutics
293. Stanford University
294. St. Jude Children’s Research Hospital
295. SOTIO
296. StrideBio
297. SR One
298. Sun Yat-sen University
299. Tactiva Therapeutics
300. Takeda Pharmaceutical
301. Takara Bio
302. Targazyme
303. Target ALS Foundation
304. TC BioPharm
305. Tesaro
306. Terumo Medical
307. Beijing Pregene Science and Technology Company
308. The First Affiliated Hospital of Guangdong Pharmaceutical University
309. The First Affiliated Hospital of Guangzhou Medical University
310. The First Affiliated Hospital of Soochow University
311. The First People's Hospital of Yunnan
312. The Pregene (ShenZhen) Biotechnology Company
313. Theravectys
314. Henan University of Traditional Chinese Medicine
315. Texas Emerging Technology Fund
316. Thermo Fisher Scientific
317. The Wistar Institute
318. Third Military Medical University
319. Third Rock Ventures
320. Third Security
321. Tianjin Medical University Cancer Institute and Hospital
322. TiGenix
323. TissueGene-C
324. Tmunity Therapeutics
325. TNK Therapeutics
326. Tongji University School of Medicine
327. TRACT Therapeutics
328. Transgene
329. Transposagen Biopharmaceuticals
330. T. Rowe Price Associates
331. TVAX Biomedical
332. TVM Capital
333. Two Blades Foundation
334. Txcell
335. UNC Lineberger Comprehensive Cancer Center
336. Union Stem Cell & Gene Engineering
337. University College London
338. University Health Network, Toronto
339. University of Birmingham
340. University of British Columbia
341. University of California
342. University of Florida
343. University of Milano-Bicocca
344. University of Minnesota
345. University of Pennsylvania
346. University of Texas
347. University of Zurich
348. Uppsala University
349. Unum Therapeutics
350. Vaccinogen
351. Valeant Pharmaceuticals
352. Vecura
353. Versant Ventures
354. Vertex Pharmaceuticals
355. VGXI
356. Viking Global Investors
357. ViroMed
358. Vor Biopharma
359. Washington University
360. Weill Cornell Medical College
361. Wellington Capital Management
362. Wuhan Union Hospital
363. Wuhan Sian Medical Technology
364. WuXi AppTec
365. Xinqiao Hospital of Chongqing
366. Xijing Hospital
367. Xuzhou Medical University
368. Zhejiang University
369. Zhujiang Hospital
370. ZIOPHARM Oncology


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Immunotherapy, an Emerging Therapeutic Option
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell Based Therapies
3.6. Evolution of T-Cell Immunotherapies
3.7. Key Considerations for T-Cell Immunotherapies
3.8. Strategies Employed for Redirection of T-Cells
3.9. Manufacturing of Engineered T-Cells
3.10. T-Cell Transduction / Transfection Methods
3.10.1. Retroviral Vectors
3.10.2. Lentiviral Vectors
3.10.3. Non-viral Transfection Methods
3.10.3.1. Sleeping Beauty Transposon
3.11. T-Cell Immunotherapy: Targeted Therapeutic Areas
3.12. T-Cell Immunotherapies: Key Challenges
4. CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY
4.1. Chapter Overview
4.2. History of Development
4.3. Anatomical Layout of Chimeric Antigen Receptor
4.4. Development Of CAR-T Therapies
4.5. Universal CAR-Ts
4.6. Preferred Routes of Administration
4.7. Toxicity Issues
4.7.1. Cytokine Release Syndrome (CRS)
4.7.2. On-Target, Off-Tumor Toxicity
4.7.3. Encephalopathy and B-Cell Aplasia
4.7.4. Neurological Toxicity
4.7.5. Anaphylaxis
4.7.6. Insertional Oncogenesis
4.7.7. Graft versus Host Disease (GVHD)
4.8. Management of Toxicity Issues
4.8.1. Pharmacological Immunosuppression
4.8.2. Target Selection
4.8.3. Safety Switches
4.8.4. Elimination Genes
4.8.5. Receptor Expression
4.9. CD19: An Attractive Target
4.10. Other Targets
4.11. Challenges Associated with CAR-T Therapy
4.11.1. Competitive Risks
4.11.2. Clinical Risks
4.11.3. Regulatory Risks
4.11.4. Commercial Risks
5. EMERGING TRENDS ON SOCIAL MEDIA
5.1. Chapter Overview
5.2. Trends on Twitter
5.2.1. Social Media Analysis: Yearly Trends on Twitter
5.2.2. Social Media Analysis: Popular Keywords on Twitter
5.3. Social Media Analysis: Most Popular Drugs on Twitter
6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. CAR-T Therapies: Pipeline Overview
6.2.1. Distribution by Type of Developer
6.2.2. Distribution by Phase of Development
6.2.3. Target Oncological Indications
6.2.3.1. Popular Target Indications
6.2.4. Popular Target Antigens
6.2.5. Distribution by Source of T-Cells
6.2.6. Distribution by Route of Administration
6.2.7. Key Industry Players
6.2.8. Key Non-Industry Players
6.3. CAR-T Therapies: Analysis of CAR Constructs
6.3.1. Analysis by Generation of CAR-T Therapies
6.3.2. Analysis by Type of scFv Antibody
6.3.3. Analysis by Type of Vector
6.3.4. Analysis by Type of Co-Stimulatory Domain(s)
7. KEY INSIGHTS
7.1. Chapter Overview
7.2. CAR-T Therapies: Analysis by Popularity of Target Antigens
7.2.1. Hematological Cancers: Popular Targets
7.2.1.1. CD19 CAR-T Therapies: Competitive Landscape
7.2.1.2. CD19 CAR-T Therapies: Clinical Trial Results of Prominent Product Candidates
7.2.1.3. BCMA CAR-T Therapies: Competitive Landscape
7.2.1.4. BCMA CAR-T Therapies: Clinical Trial Results of Prominent Product Candidates
7.2.2. Solid Tumors: Popular Targets
7.2.2.1. Meso CAR-T Therapies: Competitive Landscape
7.2.2.2. GD2 CAR-T Therapies: Competitive Landscape
7.3. CAR-T Therapies: Clinical Trial Trends, 2009-2018
7.3.1. Analysis by Trial Registration Year
7.3.2. Geographical Analysis by Number of Registered Trials
7.4. CAR-T Therapies: Clinical Trial Overview
7.4.1. Clinical Trial Analysis: Distribution by Phase of Development
7.4.2. Clinical Trial Analysis: Distribution by Patient Segment
7.4.3. Clinical Trial Analysis: Distribution by Type of Therapy
7.5. CAR-T Therapies: Key Opinion Leaders
7.5.1. Most Prominent Key Opinion Leaders
8. MARKETED AND LATE-STAGE CAR-T THERAPY PROFILES
8.1. Chapter Overview
8.2. Kymriah® / Tisagenlecleucel / CTL019 (Novartis)
8.2.1. Therapy Overview
8.2.2. History of Development
8.2.3. Current Development Status
8.2.4. Key Clinical Trial Results
8.2.5. Dosage Regimen, Price and Manufacturing
8.3. Yescarta® / Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
8.3.1. Therapy Overview
8.3.2. Current Development Status
8.3.3. Key Clinical Trial Results
8.3.4. Dosage Regimen, Price and Manufacturing
8.3.5. Next Generation eACT CAR Candidates
8.4. JCAR (Juno Therapeutics)
8.4.1. Therapy Overview
8.4.2. CAR-T Design
8.4.3. Development Status
8.4.4. Key Clinical Results
8.4.4.1. JCAR014
8.4.4.2. JCAR017
8.4.4.3. JCAR018
8.4.5. Dosage Regimen and Manufacturing
8.5. CAR-T Series (Cellular Biomedicine Group)
8.5.1. Therapy Overview
8.5.2. History of Development
8.5.3. Current Development Status
8.5.4. Key Clinical Trial Results
8.5.4.1. CBM-EGFR.1
8.5.4.2. CBM-C19.1
8.5.4.1. CBM-C20.1
8.5.4.2. CBM-C30.1
8.5.5. Dosage Regimen and Manufacturing
8.5.6. Patent Portfolio
8.6. CD19 CAR (Takara Bio)
8.6.1. Therapy Overview
8.6.2. Current Developmental Status
8.6.3. Key Clinical Trial Results
8.6.4. Dosage Regimen and Manufacturing
8.7. Dual Targeting CAR-T Cell therapies (Autolus)
8.7.1. Therapy Overview
8.7.2. Current Development Status
8.7.3. Key Clinical Trial Results
8.7.4. Dosage Regimen and Manufacturing
8.8. CAR-T Therapies (Sinobioway Cell Therapy)
8.8.1. Therapy Overview
8.8.2. Current Development Status
9. KEY THERAPEUTIC AREAS CAR-T THERAPIES
9.1. Chapter Overview
9.2. Hematological Malignancies
9.2.1. Leukemia and Lymphoma
9.2.1.1. Leukemia: Introduction and Epidemiology
9.2.1.1.1. Acute Myeloid Leukemia (AML)
9.2.1.1.2. Chronic Myeloid Leukemia (CML)
9.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
9.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
9.2.1.2. Lymphoma: Introduction and Epidemiology
9.2.1.3. Current Treatment Landscape
9.2.1.3.1. Targeted Therapies
9.2.1.4. CAR-T Therapy and Research Landscape
9.2.2. Multiple Myeloma
9.2.2.1. Introduction and Epidemiology
9.2.2.2. Current Treatment Landscape
9.2.2.3. CAR-T Therapy and Research Landscape
9.3. Solid Tumors
9.3.1. Metastatic Melanoma
9.3.1.1. Introduction and Epidemiology
9.3.1.2. Current Treatment Landscape
9.3.1.3. CAR-T Therapy and Research Landscape
9.3.2. Lung Cancer
9.3.2.1. Introduction and Epidemiology
9.3.2.2. Current Treatment Landscape
9.3.2.3. CAR-T Therapy and Research Landscape
9.3.3. Bladder Cancer
9.3.3.1. Introduction and Epidemiology
9.3.3.2. Current Treatment Landscape
9.3.3.3. CAR-T Therapy and Research Landscape
9.3.4. Kidney Cancer
9.3.4.1. Introduction and Epidemiology
9.3.4.2. Current Treatment Landscape
9.3.4.3. CAR-T Therapy and Research Landscape
9.3.5. Ovarian Cancer
9.3.5.1. Introduction and Epidemiology
9.3.5.2. Current Treatment Landscape
9.3.5.3. CAR-T Therapy and Research Landscape
9.3.6. Breast Cancer
9.3.6.1. Introduction and Epidemiology
9.3.6.2. Current Treatment Landscape
9.3.6.3. CAR-T Therapy and Research Landscape
10. EMERGING TECHNOLOGIES
10.1. Chapter Overview
10.2. Genome Editing Technologies
10.2.1. Technology Overview
10.2.2. Applications
10.2.3. Emerging Technology Platforms Used in CAR-T Therapies
10.2.3.1. CRISPR/Cas9 System
10.2.3.1.1. Key Components and Function
10.2.3.1.2. Mechanism of Action
10.2.3.1.3. Targeting Efficiency and Challenges
10.2.3.1.4. Next-GEN CRISPR Technology
10.2.3.1.5. Technology Providers
10.2.3.2. TALENs
10.2.3.2.1. Key Components and Function
10.2.3.2.2. Mechanism of Action
10.2.3.2.3. Advantages and Challenges
10.2.3.2.4. Technology Providers
10.2.3.3. megaTAL
10.2.3.3.1. Technology Providers
10.2.3.4. Zinc Finger Nuclease
10.2.3.4.1. Technology Providers
10.3. Designing T-Cell Therapies with Improved Characteristics
10.3.1. Technologies for Targeting Multiple Cancers
10.3.1.1. NKR-T Platform (Celyad)
10.3.2. Technologies for Improved Safety
10.3.2.1. Armored CAR and EGFRt technology (Juno Therapeutics)
10.3.2.2. RheoSwitch Therapeutic System (Intrexon)
10.3.2.3. Inducible Caspase 9 Safety Switch (Bellicum Pharmaceuticals)
10.3.2.3.1. CaspaCIDe Technology
10.3.2.3.2. CIDeCAR Technology
10.3.2.3.3. GoCAR-T Technology
10.3.2.4. On-Off Switch, Multiple Companies
10.3.2.4.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
10.3.2.4.2. On-Off Switch (Theravectys)
10.3.2.5. Other Technologies to Improve CAR-T Safety
10.3.3. Allogeneic Technologies
10.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
10.3.3.2. Allogeneic Platform (Celyad)
10.3.3.3. Allogeneic Platform (Cellectis)
11. CASE STUDY: CELL THERAPY MANUFACTURING
11.1. Chapter Overview
11.2. Introduction
11.3. Key Challenges
11.4. Current Trends
11.4.1. Companies with In-House Capabilities
11.4.2. Contract Manufacturers
11.5. Key Considerations for a Manufacturing Site
11.6. Regulatory Landscape
12. T-CELL IMMUNOTHERAPY: COST PRICE ANALYSIS
12.1. Chapter Overview
12.2. Factors Contributing to the Price of Cell / Gene Therapies
12.3. Pricing Models for T-Cell Immunotherapies
12.3.1. On the Basis of Associated Costs
12.3.2. On the Basis of Competition
12.3.3. On the Basis of Patient Segment
12.3.4. On the Basis of Expert Opinions
12.4. Reimbursement Considerations for T-Cell Immunotherapies
12.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapy
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Scope and Limitations
13.3. Forecast Methodology
13.4. Overall CAR-T Therapy Market
13.4.1. CAR-T Therapy Market: Distribution by Geography
13.4.2. CAR-T Therapy Market: Distribution by Target Indications
13.5. CAR-T Therapy Market: Product-Wise Sales Forecasts
13.5.1. Kymriah® (Novartis)
13.5.1.1. Target Population
13.5.1.2. Sales Forecast
13.5.2. Yescarta® (Gilead Sciences)
13.5.2.1. Target Population
13.5.2.2. Sales Forecast
13.5.3. bb2121 (Celgene / bluebird bio)
13.5.3.1. Target Population
13.5.3.2. Sales Forecast
13.5.4. MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center)
13.5.4.1. Target Population
13.5.4.2. Sales Forecast
13.5.5. CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University)
13.5.5.1. Target Population
13.5.5.2. Sales Forecast
13.5.6. GPC3 CAR-T (Shanghai GeneChem)
13.5.6.1. Target Population
13.5.6.2. Sales Forecast
13.5.7. TBI-1501 (Takara Bio / Jichi Medical University)
13.5.7.1. Target Population
13.5.7.2. Sales Forecast
13.5.8. JCAR017 (Juno Therapeutics / Celgene)
13.5.8.1. Target Population
13.5.8.2. Sales Forecast
13.5.9. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
13.5.9.1. Target Population
13.5.9.2. Sales Forecast
13.5.10. PCAR-019 (PersonGen BioTherapeutics)
13.5.10.1. Target Population
13.5.10.2. Sales Forecast
13.5.11. AUTO2 (Autolus)
13.5.11.1. Target Population
13.5.11.2. Sales Forecast
13.5.12. AUTO3 (Autolus)
13.5.12.1. Target Population
13.5.12.2. Sales Forecast
13.5.13. BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital)
13.5.13.1. Target Population
13.5.13.2. Sales Forecast
13.5.14. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology / Henan Cancer Hospital)
13.5.14.1. Target Population
13.5.14.2. Sales Forecast
13.5.15. CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University)
13.5.15.1. Target Population
13.5.15.2. Sales Forecast
13.5.16. LCAR-B38M CAR-T (Nanjing Legend Biotech)
13.5.16.1. Target Population
13.5.16.2. Sales Forecast
13.5.17. CD19 CAR-T (Shanghai Bioray Laboratory)
13.5.17.1. Target Population
13.5.17.2. Sales Forecast
14. PROMOTIONAL ANALYSIS
14.1. Chapter Overview
14.2. Channels Used for Promotional Campaigns
14.3. Summary of Product Website Analysis
14.4. Summary of Patient Support Services and Informative Downloads
14.5. Kymriah®: Promotional Analysis
14.5.1. Drug Overview
14.5.2. Product Website Analysis
14.5.2.1. Messages for Healthcare Professionals
14.5.2.2. Messages for Patients
14.5.3. Patient Support Services and Informative Downloads
14.5.4. Other Promotional Activities
14.5.4.1. Presence in Conferences
14.6. Yescarta®: Promotional Analysis
14.6.1. Drug Overview
14.6.2. Product Website Analysis
14.6.2.1. Messages for Healthcare Professionals
14.6.2.2. Messages for Patients
14.6.3. Patient Support Services and Informative Downloads
14.6.4. Other Promotional Activities
14.6.4.1. Presence in Conferences
15. COMPANY PROFILES
15.1. Chapter Overview
15.2. Autolus
15.3. bluebird bio
15.4. CARsgen Therapeutics
15.5. Celgene
15.6. Cell Medica
15.7. Cellectis
15.8. Cellular Biomedicine Group
15.9. Innovative Cellular Therapeutics
15.10. Kite Pharma (A Gilead Sciences Company)
15.11. Novartis
15.12. Sinobioway Cell Therapy
15.13. Takara Bio
15.14. ZIOPHARM Oncology
16. CONCLUSION
16.1. CAR-T Therapies Market is Characterized by a Robust Pipeline of Over 350 Product Candidates Being Developed for Various Oncological Indications
16.2. The Primary Focus of CAR-Based Therapeutic Interventions is on Hematological Malignancies and Solid Tumors
16.3. Both Established Players and Start-Ups are Actively Involved in Developing CAR-T Therapies; Academic Institutes Continue to Make Significant Contributions to the Innovation in this Domain
16.4. Several Innovative Technology Platforms have been Developed, and are Expected to Enable the Development of Better Therapies, With Favorable Safety and Efficacy Profiles
16.5. Owing to High R&D Investments, CAR-T Therapies Bear Premium Price Tags; Developers are Striving to Offer Reimbursement Plans and Implement Various Promotional Strategies to Achieve Commercial Success
16.6. Post the Approval of Multiple Late-Phase Product Candidates, the Market is Anticipated to Grow at a Rapid Pace in the Foreseen Future
17. EXECUTIVE INSIGHTS
17.1. Chapter Overview
17.2. Enkhtsetseg Purev, Assistant Professor of Medicine, University of Colorado (Q1 2018)
17.3. Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology, Changhai Hospital (Q4 2017)
17.4. Brian Dattilo, Manager of Business Development, Waisman Biomanufacturing (Q1 2017)
17.5. Miguel Forte, Chief Operating Officer, TxCell (Q3 2016)
17.6. Adrian Bot, Vice President, Scientific Affairs, Kite Pharma (Q1, 2016)
17.7. Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development, Theravectys (Q3, 2015)
17.8. Vincent Brichard, Vice President, Immuno-Oncology, Celyad (Q3 2015)
18. APPENDIX 1: TABULATED DATA
19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS 
LIST OF FIGURES
Figure 3.1 The Four Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 3Es of the Immune System
Figure 3.5 Strategies Employed for the Redirection of T-Cells
Figure 3.6 T-Cell Manufacturing: General Procedure
Figure 3.7 T-Cell Immunotherapies: Targeted Therapeutic Areas
Figure 3.8 T-Cell Immunotherapies: Benefits and Key Challenges
Figure 4.1 Historical Timeline: Development of CAR-T cells
Figure 4.2 CAR-T: Structure and Domains
Figure 4.3 CAR Generations: Structural Layout
Figure 4.4 Development of CAR-T Therapies
Figure 4.5 Challenges Associated with CAR-T Therapy
Figure 5.1 Social Media Analysis: Twitter Trends, January 2012-November 2017
Figure 5.2 Social Media Analysis: Popular Keywords on Twitter, January 2012-November 2017
Figure 5.3 Social Media Analysis: Twitter, Most Popular Candidates, January 2012-November 2017
Figure 6.1 CAR-T Therapy Pipeline: Distribution by Type of Developer
Figure 6.2 CAR-T Therapy Pipeline: Distribution by Phase of Development
Figure 6.3 CAR-T Therapy Pipeline: Distribution by Target Therapeutic Area
Figure 6.4 CAR-T Therapy Pipeline: Popular Target Indications
Figure 6.5 CAR-T Therapy Pipeline: Distribution by Target Antigen
Figure 6.6 CAR-T Therapy Pipeline: Distribution by Source of T-Cells
Figure 6.7 CAR-T Therapy Developer Landscape: Distribution by Source of T-Cells
Figure 6.8 CAR-T Therapy Pipeline: Distribution by Route of Administration
Figure 6.9 CAR-T Therapy Pipeline: Active Industry Players in Clinical Development
Figure 6.10 CAR-T Therapy Pipeline: Active Industry Players in Preclinical Development
Figure 6.11 CAR-T Therapy Pipeline: Active Non-Industry Players in Clinical Development
Figure 6.12 CAR-T Therapy Pipeline: Active Non-Industry Players in Preclinical Development
Figure 6.13 CAR-Construction: Distribution by Generation of CAR-T Therapies
Figure 6.14 CAR-Construction: Distribution by Type of scFv Used in CAR-T Therapies
Figure 6.15 CAR-Construction: Distribution by Type of Vector
Figure 6.16 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Figure 7.1 CAR-T Therapies: Popular Targets in Hematological Cancer
Figure 7.2 CAR-T Therapies: Popular Targets in Solid Tumor
Figure 7.3 CAR-T Clinical Trials: Cumulative Trend (2009-2018)
Figure 7.4 CAR-T Clinical Trials: Geographic Landscape (Pre-2016 and 2018)
Figure 7.5 CAR-T Therapies: Distribution of Clinical Trials by Phase of Development
Figure 7.6 CAR-T Therapies: Distribution of Clinical Trials by Patient Segment
Figure 7.7 CAR-T Therapies: Distribution of Clinical Trials by Type of Therapy
Figure 7.8 CAR-T Therapies: Geographical Distribution of Key Opinion Leaders
Figure 7.9 CAR-T Therapies: Prominent Key Opinion Leaders
Figure 8.1 Kymriah®: Industry Sponsored Clinical Trial Design
Figure 8.2 Kymriah®: Non-Industry Sponsored Clinical Trial Design
Figure 8.3 Yescarta®: Clinical Trial Design
Figure 8.4 Manufacturing of CD19 CAR-T Cells: Process Comparison
Figure 8.5 JCAR Series: Industry Sponsored Clinical Trial Design
Figure 8.6 JCAR Series: Non-Industry Sponsored Clinical Trial Design
Figure 8.7 Cellular Biomedicine’s CAR-T Series: Clinical Trial Design
Figure 8.8 Takara Bio’s CD19 CAR-T: Clinical Trial Design
Figure 8.9 Autolus’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Design
Figure 8.10 Sinobioway Cell Therapy’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Design
Figure 9.1 Leukemia: Classification
Figure 9.2 Leukemia: Global Epidemiological Distribution
Figure 9.3 Lymphoma: Global Epidemiological Distribution
Figure 9.4 Multiple Myeloma: Global Epidemiological Distribution
Figure 9.5 Melanoma: Global Epidemiological Distribution
Figure 9.6 Lung Cancers: Classification
Figure 9.7 Lung Cancer: Global Epidemiological Distribution
Figure 9.8 Bladder Cancer: Global Epidemiological Distribution
Figure 9.9 Kidney Cancer: Global Epidemiological Distribution
Figure 9.10 Ovarian Cancer: Global Epidemiological Distribution
Figure 9.11 Breast Cancer: Global Epidemiological Distribution
Figure 10.1 Genome Editing Technologies: Applications
Figure 10.2 Genome Editing: Emerging Technology Platforms Used in CAR-T Therapies
Figure 10.3 Key Technologies to Enhance Features / Characteristics of CAR-T Therapies
Figure 10.4 Cellectis: Properties of Enhanced T-Cell Platform
Figure 10.5 Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 11.1 Cell Therapy Manufacturing: Key Steps
Figure 11.2 Cell Therapy Manufacturing: Scenarios
Figure 11.3 T-Cell Immunotherapy Manufacturing: Key Collaborations
Figure 12.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 13.1 Overall CAR-T Therapy Market Forecast, 2018-2030: Base Scenario (USD Billion)
Figure 13.2 CAR-T Therapy Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Figure 13.3 CAR-T Therapy Market: Distribution by Target Indication, 2018, 2025 and 2030 (USD Billion)
Figure 13.4 Kymriah® (Novartis): Current Status of Development
Figure 13.5 Kymriah® (Novartis) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.6 Yescarta® (Gilead Sciences): Current Status of Development
Figure 13.7 Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.8 bb2121 (Celgene / bluebird bio): Current Status of Development
Figure 13.9 bb2121 (Celgene / bluebird bio) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.10 MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center): Current Status of Development
Figure 13.11 MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.12 CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University): Current Status of Development
Figure 13.13 CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.14 GPC3 CAR-T (Shanghai GeneChem): Current Status of Development
Figure 13.15 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.16 TBI-1501 (Takara Bio / Jichi Medical University): Current Status of Development
Figure 13.17 TBI-1501 (Takara Bio / Jichi Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.18 JCAR017 (Juno Therapeutics / Celgene): Current Status of Development
Figure 13.19 JCAR017 (Juno Therapeutics / Celgene) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.20 IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Current Status of Development
Figure 13.21 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.22 PCAR-019 (PersonGen BioTherapeutics): Current Status of Development
Figure 13.23 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.24 AUTO2 (Autolus): Current Status of Development
Figure 13.25 AUTO2 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.26 AUTO3 (Autolus): Current Status of Development
Figure 13.27 AUTO3 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.28 BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital): Current Status of Development
Figure 13.29 BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.30 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital): Current Status of Development
Figure 13.31 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.32 CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University): Current Status of Development
Figure 13.33 CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.34 LCAR-B38M CAR-T (Nanjing Legend Biotech): Current of Development
Figure 13.35 LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.36 CD19 CAR-T (Shanghai Bioray Laboratory): Current Status of Development
Figure 13.37 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 14.1 Promotional / Marketing Strategy: Product Website Analysis
Figure 14.2 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Figure 14.3 Product Website Analysis: Kymriah®, Messages for Healthcare Professionals
Figure 14.4 Product Website Analysis: Kymriah®, Messages for Patients
Figure 14.5 Product Website Analysis: Kymriah®, Patient Support Program
Figure 14.6 Kymriah®, Presence in Conferences
Figure 14.7 Product Website Analysis: Yescarta®, Messages for Healthcare Professionals
Figure 14.8 Product Website Analysis: Yescarta®, Messages for Patients
Figure 14.9 Product Website Analysis: Yescarta®, Kite Konnect
Figure 14.10 Product Website Analysis: Yescarta®, Platform for Products Complaints, Reporting Adverse Events and Requesting Medical Information
Figure 14.11 Yescarta®, Presence in Conferences
Figure 16.1 CAR-T Therapy Market Landscape: Non-Industry Participants
Figure 16.2 CAR-T Therapy Market Landscape: Industry Participants
Figure 16.3 CAR-T Therapy Market Forecast, 2018, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Billion)
LIST OF TABLES
Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 4.1 Key Characteristics of CAR-T Cells
Table 4.2 Comparison Between First and Second-Generation CARs
Table 4.3 Grading Criteria for CRS
Table 4.4 Safety Switches under Development for CAR-T Therapy
Table 4.5 CD19 CAR-T Cells: Preclinical Results
Table 4.6 Other Targets under Clinical / Preclinical Studies for CAR-T Therapy
Table 6.1 CAR-T Therapies: Clinical Pipeline
Table 6.2 CAR-T Therapies: Preclinical Pipeline
Table 6.3 CAR-T Therapies: Information on Constructs of Clinical Candidates,
Table 7.1 CD19 CAR-T Therapies: Competitive Landscape
Table 7.2 CD19 CAR-T Therapies: Clinical Outcomes
Table 7.3 BCMA CAR-T Therapies: Competitive Landscape
Table 7.4 BCMA CAR-T Therapies: Clinical Outcomes
Table 7.5 Meso CAR-T Therapies: Competitive Landscape
Table 7.6 GD2 CAR-T Therapies: Competitive Landscape
Table 7.7 CAR-T Therapies: Clinical Trials
Table 7.8 CAR-T Therapies: Principle Investigators
Table 8.1 Kymriah®: Current Status of Development
Table 8.2 Kymriah®: Clinical Trial Endpoints (ALL)
Table 8.3 Kymriah®: Clinical Trial Endpoints (CLL/MM/NHL)
Table 8.4 Yescarta®: Current Status of Development
Table 8.5 Yescarta®: Clinical Trial Endpoints
Table 8.6 Yescarta®: ZUMA-1 Phase II (6 months Follow-Up)
Table 8.7 Yescarta®: ZUMA-1 Phase II Results (≥3 months Follow-Up)
Table 8.8 Yescarta®: ZUMA-1 Phase I & Phase II Results (3 months Follow-Up)
Table 8.9 JCAR Series: Molecules in Clinical Development
Table 8.10 JCAR: CAR-T Design
Table 8.11 JCAR014: Current Status of Development
Table 8.12 JCAR017: Current Status of Development
Table 8.13 JCAR018: Current Status of Development
Table 8.14 JCAR020: Current Status of Development
Table 8.15 JCAR023: Current Status of Development
Table 8.16 JCAR024: Current Status of Development
Table 8.17 JCAR Series: Clinical Trial Endpoints (Phase II)
Table 8.18 JCAR Series: Clinical Trial Endpoints (Phase I)
Table 8.19 JCAR: Dosage Regimen
Table 8.20 CBM CAR-T Series: Clinical Products,
Table 8.21 CBM-CD19.1 CAR-T: Current Status of Development
Table 8.22 CBM-CD20 CAR-T: Current Status of Development
Table 8.23 CBM-CD30.1 CAR-T: Current Status of Development
Table 8.24 CBM-EGFR.1 CAR-T: Current Status of Development
Table 8.25 CBM CAR-T Series: Clinical Trial Endpoints
Table 8.26 CBM CAR-T Series: Patent Portfolio
Table 8.27 Takara Bio’s CD19 CAR-T: Current Status of Development
Table 8.28 Takara Bio’s CD19 CAR-T: Clinical Trial Endpoints
Table 8.29 TBI-1501: Dosage Regimen
Table 8.30 AUTO2: Current Status of Development
Table 8.31 AUTO3: Current Status of Development
Table 8.32 Autolus’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.33 Sinobioway Cell Therapy’s CD19 CAR-T Therapy: Current Status of Development
Table 8.34 Sinobioway Cell Therapy’s EPCAM CAR-T Therapy: Current Status of Development
Table 8.35 Sinobioway Cell Therapy’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.36 Phase I/II or Phase II CAR-T Therapies from the Industry Players
Table 9.1 Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 9.2 Leukemia: List of Marketed Targeted Therapeutics
Table 9.3 Lymphoma: List of Marketed Targeted Therapeutics
Table 9.4 CAR-T Therapies: Targets under Investigation for Leukemia
Table 9.5 CAR-T Therapies: Targets under Investigation for Lymphoma
Table 9.6 Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 9.7 CAR-T Therapies: Targets under Investigation for Multiple Myeloma
Table 9.8 Melanoma: List of Marketed Targeted Therapeutics
Table 9.9 Lung Cancer: List of Marketed Targeted Therapeutics
Table 9.10 CAR-T Therapies: Targets under Investigation for Lung Cancer
Table 9.11 Bladder Cancer: List of Marketed Targeted Therapeutics
Table 9.12 Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
Table 9.13 Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 9.14 CAR-T Therapies: Targets under Investigation for Ovarian Cancer
Table 9.15 Breast Cancer: List of Marketed Targeted Therapeutics
Table 9.16 CAR-T Therapies: Targets under Investigation for Breast Cancer
Table 10.1 Editas Medicine: CRISPR/Cas9 Technology, Research Publications
Table 10.2 Editas Medicine: Funding Instances
Table 10.3 Editas Medicine: Collaborations
Table 10.4 Intellia Therapeutics: CRISPR/Cas9 Technology, Research Publications
Table 10.5 Intellia Therapeutics: Funding Instances
Table 10.6 Intellia Therapeutics: Collaborations
Table 10.7 CRISPR Therapeutics: CRIPSR/Cas9 Technology, Research Publications
Table 10.8 CRISPR Therapeutics: Funding Instances
Table 10.9 CRISPR Therapeutics: Collaborations
Table 10.10 Cellectis: Funding Instances
Table 10.11 Cellectis: Collaborations
Table 10.12 bluebird bio: megaTAL Technology, Research Publications
Table 10.13 bluebird bio: Funding Instances
Table 10.14 bluebird bio: Collaborations
Table 10.15 Sangamo Therapeutics: Funding Instances
Table 10.16 Sangamo Therapeutics: Collaborations
Table 10.17 Celyad: Funding Instances
Table 10.18 Celyad: Collaborations
Table 10.19 Intrexon: Funding Instances
Table 10.20 Intrexon: Collaborations
Table 10.21 Bellicum Pharmaceuticals: Key Switch Technologies
Table 10.22 Bellicum Pharmaceuticals: Switch Technologies, Research Publications
Table 10.23 Bellicum Pharmaceuticals: Funding Instances
Table 10.24 Bellicum Pharmaceuticals: Collaborations
Table 10.25 Theravectys: Funding Instances
Table 10.26 Technologies For CAR-T Safety Enhancement
Table 10.27 Formula Pharmaceuticals: Collaborations
Table 10.28 Celyad: Collaborations
Table 11.1 Cell Therapy Manufacturing: Companies with In-house Capabilities
Table 11.2 Cell Therapy Manufacturing: Contract Manufacturers
Table 12.1 Price of Marketed Gene / Cell Therapies
Table 12.2 Price of Marketed Targeted Drugs
Table 12.3 T-Cell Immunotherapies: Expert Opinions on Pricing
Table 12.4 CAR-T Therapies: Reimbursement Landscape
Table 13.1 CAR-T Therapies: List of Forecasted Molecules
Table 14.1 Kymriah: Drug Overview
Table 14.2 Yescarta: Drug Overview
Table 15.1 Autolus: Company Profile
Table 15.2 bluebird bio: Company Profile
Table 15.3 CARsgen Therapeutics: Company Profile
Table 15.4 Celgene: Company Profile
Table 15.5 Cell Medica: Company Profile
Table 15.6 Cellectis: Company Profile
Table 15.7 Cellular Biomedicine Group: Company Profile
Table 15.8 Innovative Cellular Therapeutics: Company Profile
Table 15.9 Kite Pharma: Company Profile
Table 15.10 Novartis: Company Profile
Table 15.11 Sinobioway Cell Therapy: Company Profile
Table 15.12 Takara Bio: Company Profile
Table 15.13 ZIOPHARM Oncology: Company Profile
Table 18.1 CAR-T Pipeline: Distribution by Type of Developer
Table 18.2 CAR-T Therapy Pipeline: Distribution by Phase of Development
Table 18.3 CAR-T Therapy Pipeline: Distribution by Target Therapeutic Area
Table 18.4 CAR-T Therapy Pipeline: Popular Target Indications
Table 18.5 CAR-T Therapy Pipeline: Distribution by Target Antigen
Table 18.6 CAR-T Therapy Pipeline: Distribution by Source of T-Cells
Table 18.7 CAR-T Therapy Pipeline: Distribution by Route of Administration
Table 18.8 CAR-T Therapy Pipeline: Active Industry Players in Clinical Development
Table 18.9 CAR-T Therapy Pipeline: Active Industry Players in Preclinical Development
Table 18.10 CAR-T Pipeline: Active Non-Industry Players in Clinical Development
Table 18.11 CAR-T Pipeline: Active Non-Industry Players in Preclinical Development
Table 18.12 CAR-Construction: Distribution by Generation of CAR-T Therapies
Table 18.13 CAR-Construction: Distribution by Type of scFv Used in CAR-T Therapies
Table 18.14 CAR-Construction: Distribution by Type of Vector
Table 18.15 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Table 18.16 CAR-T Therapies: Popular Targets in Hematological Cancer
Table 18.17 CAR-T Therapies: Popular Targets in Solid Tumor
Table 18.18 CAR-T Clinical Trials: Cumulative Trend (Pre-2012-2018)
Table 18.19 CAR-T Clinical Trials: Geographic Landscape (Pre-2016 and 2018)
Table 18.20 CAR-T Therapies: Distribution of Clinical Trials by Phase of Development
Table 18.21 CAR-T Therapies: Distribution of Clinical Trials by Patient Segment
Table 18.22 CAR-T Therapies: Distribution of Clinical Trials by Type of Therapy
Table 18.23 Overall CAR-T Therapy Market Forecast, 2018-2030: Conservative Scenario (USD Billion)
Table 18.24 Overall CAR-T Therapy Market Forecast, 2018-2030: Base Scenario (USD Billion)
Table 18.25 Overall CAR-T Therapy Market Forecast, 2018-2030: Optimistic Scenario (USD Billion)
Table 18.26 CAR-T Therapy Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Table 18.27 CAR-T Therapy Market: Distribution by Target Indication, 2025 and 2030 (USD Billion)
Table 18.28 Kymriah® (Novartis) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.29 Kymriah® (Novartis) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.30 Kymriah® (Novartis) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.31 Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.32 Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.33 Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.34 bb2121 (Celgene / bluebird bio) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.35 bb2121 (Celgene / bluebird bio) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.36 bb2121 (Celgene / bluebird bio) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.37 MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.38 MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.39 MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.40 CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.41 CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.42 CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.43 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.44 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.45 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.46 TBI-1501 (Takara Bio / Jichi Medical University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.47 TBI-1501 (Takara Bio / Jichi Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.48 TBI-1501 (Takara Bio / Jichi Medical University) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.49 JCAR017 (Juno Therapeutics / Celgene) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.50 JCAR017 (Juno Therapeutics / Celgene) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.51 JCAR017 (Juno Therapeutics / Celgene) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.52 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.53 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.54 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.55 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.56 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.57 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.58 AUTO2 (Autolus) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.59 AUTO2 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.60 AUTO2 (Autolus) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.61 AUTO3 (Autolus) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.62 AUTO3 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.63 AUTO3 (Autolus) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.64 BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.65 BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.66 BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.67 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.68 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.69 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.70 CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.71 CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.72 CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.73 LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.74 LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.75 LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.76 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.77 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.78 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.79 CAR-T Therapy Market Forecast, 2018, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report